Newest studies
Every summary in our library, newest first, as a dated timeline.
Showing 8,051–8,075 of 27,380 studies, newest first · page 323 of 1096.
January 2023 25
-
2023-01-06
Validity and reliability of a computerized cognitive function evaluation battery (CogEvo) as a screening tool
41/100 ✓ Peer-reviewed Cognitive tests and assessment PCN reports : psychiatry and clinical neurosciences
Key finding: Exploratory factor analysis revealed the orientation/spatial cognitive function (orientation and spatial cognition) and attention/executive function (attention, memory, and execution) factors. +4 more findings
Full summary, score breakdown and related studies → Original source
-
2023-01-06
Risk factors for falls among community-dwelling older adults: A systematic review and meta-analysis
78/100 ✓ Peer-reviewed Clinical safety Frontiers in medicine
Key finding: This study provides preliminary evidence that falls among community-dwelling older adults are associated with factors such as age, female gender, fear of falling, history of falls, unclear vision, depression, and balance disorders. +3 more findings
Full summary, score breakdown and related studies → Original source
-
2023-01-06
Mediterranean Diet, Ketogenic Diet or MIND Diet for Aging Populations with Cognitive Decline: A Systematic Review
81/100 ✓ Peer-reviewed Prevention trials Life (Basel, Switzerland)
Key finding: Only RCTs were included in this study; there were eleven studies ( n = 2609 participants) of the Mediterranean diet, seven studies ( n = 313) of the ketogenic diet and one study ( n = 37) of the MIND diet. +3 more findings
Full summary, score breakdown and related studies → Original source
-
2023-01-06
Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study
53/100 ✓ Peer-reviewed Brain scans and imaging eLife
Key finding: Both FC-BAG and S-BAG are elevated in CI participants. +4 more findings
Full summary, score breakdown and related studies → Original source
-
2023-01-06
FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
15/100 ⚠ Regulatory decision — not a study Treatments U.S. Food and Drug Administration (announced via Biogen press release)
Key finding: Accelerated approval based on amyloid-PET reduction from Phase 2 data, not yet on proven cognitive benefit +2 more findings
Full summary, score breakdown and related studies → Original source
-
2023-01-05
Enrichment of dementia caregiving relationships through psychosocial interventions: A scoping review
41/100 ✓ Peer-reviewed Caregiving Frontiers in medicine
Key finding: Psychosocial interventions generating enrichment among dyads mainly involved supporting dyadic engagement in shared activities, carer education or training, or structural change to the environment around PLWD. +4 more findings
Full summary, score breakdown and related studies → Original source
-
2023-01-05
Psychiatric symptoms of frontotemporal dementia and subcortical (co-)pathology burden: new insights
55/100 ✓ Peer-reviewed Brain tissue and pathology Brain : a journal of neurology
Key finding: Elaborating on the results, we validated one finding using a quantitative assessment of TDP-43 pathology in the granular layer of the hippocampus in FTLD-TDP brain donors with (n = 15) and without (n = 15) hallucinations. +2 more findings
Full summary, score breakdown and related studies → Original source
-
2023-01-05
Single-cell-led drug repurposing for Alzheimer's disease
41/100 ✓ Peer-reviewed Drug development Scientific reports
Key finding: Using single-cell RNA sequencing data of brain tissues from patients with Alzheimer's disease, genome-wide association study results, and multiple gene annotation resources, we built a multi-cellular Alzheimer's disease molecular network that we leveraged for gaining cell-specific insights into Alzheimer's disease pathophysiology and for the identification of drug repurposing candidates.
Full summary, score breakdown and related studies → Original source
-
2023-01-05
Lecanemab in Early Alzheimer's Disease
74/100 ✓ Peer-reviewed Clinical trials New England Journal of Medicine
Key finding: n=1,795 (898 lecanemab, 897 placebo); 18-month double-blind Phase 3 trial +2 more findings
Full summary, score breakdown and related studies → Original source
-
2023-01-04
Polygenic Effect on Tau Pathology Progression in Alzheimer's Disease
68/100 ✓ Peer-reviewed Genetics Annals of neurology
Key finding: We found that a higher PGS was associated with higher rates of tau-PET accumulation, in particular at elevated amyloid-PET levels. +3 more findings
Full summary, score breakdown and related studies → Original source
-
2023-01-03
Jacob-induced transcriptional inactivation of CREB promotes Aβ-induced synapse loss in Alzheimer's disease
41/100 ✓ Peer-reviewed Disease mechanisms The EMBO journal
Key finding: Here, we report that Aβ elicits nucleocytoplasmic trafficking of Jacob, a protein that connects a NMDA-receptor-derived signalosome to CREB, in AD patient brains and mouse hippocampal neurons. +4 more findings
Full summary, score breakdown and related studies → Original source
-
2023-01-03
Age- and sex-specific modifiable risk factor profiles of dementia: evidence from the UK Biobank
55/100 ✓ Peer-reviewed Long-term cohort studies European journal of epidemiology
Key finding: To characterize the age- and sex-specific modifiable risk factor profiles of dementia, we included 497,401 UK Biobank participants (mean age = 56.5 years) without dementia at baseline (2006-2010) and followed them until March 2021. +3 more findings
Full summary, score breakdown and related studies → Original source
-
2023-01-03
Association of New Use of Antihypertensives That Stimulate vs Inhibit Type 2 and 4 Angiotensin II Receptors With Dementia Among Medicare Beneficiaries
69/100 ✓ Peer-reviewed Treatments JAMA network open
Key finding: This cohort study of Medicare beneficiaries suggests that use of antihypertensive medications that stimulate type 2 and 4 angiotensin II receptors was associated with lower risk of ADRD compared with antihypertensive medications that inhibit these receptors. +4 more findings
Full summary, score breakdown and related studies → Original source
-
2023-01-03
Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline
51/100 ✓ Peer-reviewed Biomarkers JAMA network open
Key finding: After disclosure, 27 patients with amyloid-positive SCD+ (median [IQR] age, 70 [66-74] years; gender: 14 men [52%]; median [IQR] education: 15 [13 to 17] years, median [IQR] Mini-Mental State Examination [MMSE] score, 29 [28 to 30]) had higher median (IQR) IES-R total score (10 [2 to 14] vs 0 [0 to 2]; P Conclusions and relevance The disclosure of a positive amyloid-PET result to patients with SCD+ was associated with a bigger psychological change, yet such change did not reach the threshold for clinical concern. +4 more findings
Full summary, score breakdown and related studies → Original source
-
2023-01-03
Association of Kidney Function With Development of Alzheimer Disease and Other Dementias and Dementia-Related Blood Biomarkers
70/100 ✓ Peer-reviewed Biomarkers JAMA network open
Key finding: Of 6256 participants (3402 women [54.4%]; mean [SD] age at baseline, 61.7 [6.6] years), 510 received an all-cause dementia diagnosis within 17 years of baseline. +2 more findings
Full summary, score breakdown and related studies → Original source
-
2023-01-01
DICE-Net: A Novel Convolution-Transformer Architecture for Alzheimer Detection in EEG Signals
45/100 ✓ Peer-reviewed Digital health tools IEEE Access
Key finding: Our results show that DICE-net achieved an accuracy of 83.28% in the AD-CN problem using Leave-One-Subject-Out validation, outperforming several baseline models, and achieving good generalization performance. +2 more findings
Full summary, score breakdown and related studies → Original source
-
2023 year only
Life-Sustaining Treatments Among Medicare Beneficiaries with and without Dementia at the End of Life
63/100 ✓ Peer-reviewed Costs and economics Journal of Alzheimer's disease : JAD
Key finding: Community dwellers with dementia were more likely than those without dementia to receive life-sustaining treatments in their last 90 days of life (advanced dementia: OR = 1.83 [1.42-2.35]; non-advanced dementia: OR = 1.16 [1.01-1.32]). +4 more findings
Full summary, score breakdown and related studies → Original source
-
2023 year only
Exploring Reasons for Differential Vulnerability and Alzheimer's Disease Risk in Racial and Ethnic Minorities
52/100 ✓ Peer-reviewed Disparities Journal of Alzheimer's disease : JAD
Key finding: When considering race/ethnicity, the presence of more vascular comorbidities drove greater vulnerability. +3 more findings
Full summary, score breakdown and related studies → Original source
-
2023 year only
Palliative care in Parkinson disease and related disorders
41/100 ✓ Peer-reviewed End-of-life care Handbook of clinical neurology
Key finding: Although neuropalliative care is a relatively new field, there is increasing evidence for its use among the degenerative parkinsonian syndromes, including idiopathic Parkinson disease, progressive supranuclear palsy, multiple system atrophy, dementia with Lewy bodies, and corticobasal syndrome. +2 more findings
Full summary, score breakdown and related studies → Original source
-
2023 year only
Editorial: Social Determinants of Maintaining Nutrition in Older Adults with Advanced Dementia
41/100 ✓ Peer-reviewed End-of-life care The journal of nutrition, health & aging
Key finding: Dysphagia is recognised as part of the frailty syndrome, especially for those at the end of life. +2 more findings
Full summary, score breakdown and related studies → Original source
-
2023 year only
miR-101a-3p Impairs Synaptic Plasticity and Contributes to Synucleinopathy
41/100 ✓ Peer-reviewed Disease mechanisms Journal of Parkinson's disease
Key finding: We found several deregulated biological processes linked to the synapse. miR-101a-3p was validated as a synaptic miRNA upregulated in aSyn Tg mice and in the cortex of dementia with Lewy bodies patients. +4 more findings
Full summary, score breakdown and related studies → Original source
-
2023 year only
ALZHEIMER'S DISEASE AND ITS RELATIONSHIP WITH THE MICROBIOTA-GUT-BRAIN AXIS
41/100 ✓ Peer-reviewed Disease mechanisms Arquivos de gastroenterologia
Key finding: The composition of the gut microbiota influences the CNS, resulting in changes in host behavior and may be related to the development of neurodegenerative diseases. +3 more findings
Full summary, score breakdown and related studies → Original source
-
2023 year only
Gut-derived β-amyloid: Likely a centerpiece of the gut-brain axis contributing to Alzheimer's pathogenesis
41/100 ✓ Peer-reviewed Disease mechanisms Gut microbes
Key finding: To achieve this goal, the expression levels of Aβ and several key proteins involved in Aβ metabolism were initially assessed in mouse gut, with key results confirmed in human tissue. +4 more findings
Full summary, score breakdown and related studies → Original source
-
2023 year only
Retinal Functional and Structural Neural Indices: Potential Biomarkers for the Monitoring of Cerebral Neurodegeneration: The Maastricht Study
63/100 ✓ Peer-reviewed Prevention and risk Journal of Alzheimer's disease : JAD
Key finding: Most risk factors under study (i.e., hyperglycemia, unhealthy diet, lower cardiorespiratory fitness, smoking, alcohol consumption, and hypertension) were significantly associated with lower retinal sensitivity and lower RNFL thickness. +1 more finding
Full summary, score breakdown and related studies → Original source
-
2023 year only
Impact of the MIND Diet on Cognition in Individuals with Dementia
70/100 ✓ Peer-reviewed Prevention and risk Journal of Alzheimer's disease : JAD
Key finding: The search generated 33 papers, which yielded 11 articles after screening. +4 more findings
Full summary, score breakdown and related studies → Original source
Browse the library by subject, with the full score breakdown →